RxDoctor Payments DataLook up a doctor →

Tegan McCormick

Internal Medicine · Champaign, ILNPI 1417222670

Payments from drug & device makers

$1,460,062in general payments, 2019–2025

Across 254 payments — averaging $5748.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1.3M
  • Eli Lilly$41K
  • Esperion Therapeutics, Inc.$26K
  • Astrazeneca UK Limited$24K
  • Alnylam Pharmaceuticals Inc.$22K
  • BD$12K
  • plus $6K from 7 others

What the payments were for

  • Food & beverage$32789%
  • Education$4011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,460,062 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$162,155
Medicare patients
260
Services billed
4,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide128$146,374
JardianceEmpagliflozin95$123,746
EliquisApixaban78$109,008
MounjaroTirzepatide68$78,256
XareltoRivaroxaban59$75,716
JanuviaSitagliptin Phosphate46$60,197
TrulicityDulaglutide45$42,343
MyrbetriqMirabegron44$34,761
LinzessLinaclotide18$26,335
WegovySemaglutide15$26,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$20,412
FarxigaDapagliflozin Propanediol30$18,001
VraylarCariprazine Hcl11$16,268
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$11,958
TradjentaLinagliptin22$11,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$27$172,699143 claims
Lilly USA, LLCMounjaro, Trulicity$31$120,599113 claims
AbbVieLinzess, Vraylar, Synthroid$208$46,14095 claims
AstraZenecaFarxiga$1,328,908$18,00130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →